Surface Oncology Stock Earnings Per Share
| SURFDelisted Stock | USD 0.96 0.03 3.23% |
Surface Oncology fundamentals help investors to digest information that contributes to Surface Oncology's financial success or failures. It also enables traders to predict the movement of Surface Stock. The fundamental analysis module provides a way to measure Surface Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Surface Oncology stock.
Surface |
Surface Oncology Company Earnings Per Share Analysis
Surface Oncology's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Surface Oncology Earnings Per Share | (1.66) X |
Most of Surface Oncology's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Surface Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Surface Oncology has an Earnings Per Share of -1.66 times. This is 119.83% lower than that of the Biotechnology sector and 65.34% lower than that of the Health Care industry. The earnings per share for all United States stocks is 153.21% higher than that of the company.
Surface Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Surface Oncology's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Surface Oncology could also be used in its relative valuation, which is a method of valuing Surface Oncology by comparing valuation metrics of similar companies.Surface Oncology is currently under evaluation in earnings per share category among its peers.
Surface Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.41 | |||
| Current Valuation | 18.31 M | |||
| Shares Outstanding | 60.82 M | |||
| Shares Owned By Insiders | 7.27 % | |||
| Shares Owned By Institutions | 46.03 % | |||
| Number Of Shares Shorted | 165.27 K | |||
| Price To Earning | 0.64 X | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 30 M | |||
| Gross Profit | (37 M) | |||
| EBITDA | (61.87 M) | |||
| Net Income | (63.59 M) | |||
| Cash And Equivalents | 156.65 M | |||
| Cash Per Share | 2.70 X | |||
| Total Debt | 56.04 M | |||
| Debt To Equity | 0.45 % | |||
| Current Ratio | 8.19 X | |||
| Book Value Per Share | 0.81 X | |||
| Cash Flow From Operations | (59.55 M) | |||
| Short Ratio | 0.45 X | |||
| Earnings Per Share | (1.66) X | |||
| Target Price | 2.38 | |||
| Number Of Employees | 35 | |||
| Beta | 1.75 | |||
| Market Capitalization | 65.69 M | |||
| Total Asset | 159.91 M | |||
| Retained Earnings | (204.33 M) | |||
| Working Capital | 112.88 M | |||
| Current Asset | 22 K | |||
| Current Liabilities | 36 K | |||
| Z Score | -1.33 | |||
| Net Asset | 159.91 M |
About Surface Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Surface Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Surface Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Surface Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Surface Stock
If you are still planning to invest in Surface Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Surface Oncology's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |